Table 10.
GRADE Evidence Profile comparing biologic agents + immunomodulators vs. immunomodulator monotherapy for achieving steroid-free remission in patients with moderate to severe ulcerative colitis. Note, the trial included infliximab and azathioprine as interventions. No trial of maintenance therapy comparing biologic agents + immunomodulators vs. immunomodulator monotherapy was identified.
|
COMBINATION THERAPY WITH BIOLOGIC AGENTS + IMMUNOMODULATORS COMPARED TO IMMUNOMODULATOR MONOTHERAPY FOR MODERATE-SEVERE ULCERATIVE COLITIS | ||||||
|---|---|---|---|---|---|---|
| Outcomes | Study event rates (95% CI) | Relative effect (95% CI) | Absolute effect* | No of participants (studies) | Quality of the evidence (GRADE) | |
| Achieving clinical remission (CRITICAL) | 18/79 (22.8%) | 31/80 (38.8%) | RR 1.70 (1.04 to 2.78) | 159 more per 1,000 (from 9 more to 406 more) | 159 (1 RCT) | ⨁⨁⨁◯1 MODERATE |
|
GRADE Working Group grades of evidence High quality: We are very confident that the true effect lies close to that of the estimate of the effect Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect | ||||||
1
Rated down for imprecision since optimal information size not met (<200 events)